Trial Profile
An Open Label, Four Week, Dose Escalating Pharmacokinetic, Pharmacodynamic, Efficacy and Safety Study of CTA018 Injection in Subjects With Stage 5 Chronic Kidney Disease With Secondary Hyperparathyroidism on Hemodialysis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Lunacalcipol (Primary)
- Indications Secondary hyperparathyroidism
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Cytochroma
- 22 May 2014 New trial record